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Summary: A new anticonvulsant compound, zonisamide (1,2 
benzisoxazole-methanesulfonamide), was studied in 10 adults 
with medically refractory partial seizures. Following a single 
oral dose of 400 mg, peak plasma levels occurred an average 
of 2.8 h after dosing, and the mean clearance from plasma was 
2.34 L/h. Whole blood concentrations were higher than plasma 
concentrations because of red blood cell binding. Steady-state 
plasma concentrations were higher than predicted from a linear 
Currently available antiepileptic drugs such as carba- 
mazepine, phenobarbital, phenytoin, and primidone are 
effective in controlling epileptic seizures in many pa- 
tients. However, there remains a large group of people 
for whom seizures cannot be controlled with drugs. In 
adults, the partial seizures (simple partial, complex par- 
tial, and partial seizures evolving to generalized sei- 
zures) are among the most difficult to control with medical 
management. There is a need to develop and test new 
compounds that may be safe and effective in the treat- 
ment of partial seizures. 
There is evidence that a new compound, zonisamide 
(1,2-benzisoxazole-3-methanesulfonamide), may be an 
effective antiepileptic drug. The anticonvulsant proper- 
ties of zonisamide were discovered through extensive 
testing of numerous 3-substituted 1,2-benzisoxazole 
compounds (Masuda et al., 1980). These properties of 
zonisamide were demonstrated in several animal models, 
including maximal electroshock seizures, maximal pen- 
tylenetetrazole-induced seizures, and kindling (Masuda 
et al., 1979, 1980; Kamei et al., 1981). The compound 
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kinetic model. In most patients, seizure frequency was reduced 
after zonisamide was substituted for a standard antiepileptic 
drug. Dose-related reversible side effects in the central nervous 
and gastrointestinal systems were observed. Most patients tol- 
erated doses between 5.2 and 12.5 mgikglday. Key Words: 
AD-81~1,2-Benzisoxazole-3-methanesulfonamide-CI 
Partial seizures-Zonisamide. 
has been shown to suppress focal spiking and spread of 
secondarily generalized seizures in experimental animals 
(Ito et al., 1980). These studies indicate that the anti- 
convulsant profile of zonisamide is similar to that of 
phenytoin or carbamazepi-ne (Masuda et al., 1980; Ka- 
mei et al., 1981). 
Masuda et al. (1979) studied the relationship of plasma 
concentrations of zonisamide, its anticonvulsant effects, 
and impaired motor function in several species. Based 
on comparisons with phenytoin, phenobarbital, and car- 
bamazepine in these animal paradigms, the authors pre- 
dicted that zonisamide would be effective clinically in 
plasma concentrations between 10 and 70 p,g/ml. 
The present protocol was designed to study the single- 
and multiple-dose pharmacokinetics of zonisamide in 
patients receiving other antiepileptic drugs, to evaluate 
the safety of zonisamide with chronic administration, 
and to provide preliminary evidence of the efficacy of 
zonisamide in controlling medically refractory partial 
seizures in humans. 
PATIENTS AND METHODS 
Six men and five women of nonchildbearing potential 
entered the study. All patients were between 19 and 50 
years of age and had at least four partial seizures per 
month, in spite of therapeutic plasma levels of two or 
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TABLE 1. Outline of experimental protocol 
Study phase Treatment Duration 
I .  Eligibility screen 
2. Baseline Two or three standard 8 wk 
3. Single-dose kinetic Single dose of 400 1 wk 
antiepileptic drugs 




4. Multiple-dose study Zonisamide every 1 wk 
12 h plus baseline 





6. Outpatient treatment Zonisamide plus 10 wk 
three standard antiepileptic drugs. Patients with more 
than four generalized tonic-clonic seizures in the 3 months 
before the study were not entered. Patients with other 
significant medical or psychiatric illnesses, with pro- 
gressive neurological disorders, or with a history of sta- 
tus epilepticus were not eligible for this study. Informed 
written consent was obtained in each case. On entering 
the study, each patient underwent complete neurological 
and general physical examinations, electrocardiograms, 
EEG, complete blood count, blood chemistry profile, 
measurement of plasma anticonvulsant levels, and uri- 
nalyses. Seizures were classified according to the Re- 
vised International classification of Epileptic Seizures 
(Dreifuss et al., 1981). One patient withdrew from the 
study in the baseline period, before receiving zonisam- 
ide. The study protocol is outlined in Table 1. 
Baseline 
The protocol included an 8-week baseline period dur- 
ing which each patient continued receiving either two or 
three standard antiepileptic drugs. The baseline treat- 
ment for each patient had previously been determined, 
on clinical grounds, to be the most effective regimen for 
that individual. The baseline treatment for each patient 
is listed in Table 2. Patients kept daily seizure logs 
throughout the study and were evaluated every 4 weeks 
during the baseline period. This evaluation included a 
review of the seizure log, interval medical history, gen- 
eral physical and neurological examinations, electrocar- 
diogram, EEG, complete blood count, blood chemistry 
profile, measurement of plasma anticonvulsant drug lev- 
els, and urinalyses. A neuropsychological test battery 
was performed at the end of the baseline period. 
Single-dose pharmacokinetic study 
Following the baseline period, a single-dose kinetic 
study was performed. A single oral dose of zonisamide 
was given on the first day. Blood samples were obtained 
at 0, 0.33, 0.67, 1, 2, 4, 8, 12, 24, 36, 48, 60, 72, 84, 
and 96 h. These samples were assayed to determine the 
plasma and whole blood concentrations of zonisamide, 
using a high-pressure liquid chromatography technique 
(Warner-Lambert). Red blood cell concentrations were 
calculated from the plasma and whole blood concentra- 
tions and the hematocrit. Formulas used for calculating 
kinetic parameters are given in the Appendix. 
Multiple-dose pharmacokinetic study 
After completion of the single-dose kinetic phase, zon- 
isamide was administered orally every 12 h. The dose 
for each patient was based on estimation of pharmaco- 
kinetic parameters derived from the single-dose kinetic 
study. An oral clearance rate was calculated for each 
patient (see Appendix for formulas). Then, based on a 
linear kinetic model, the dose required to achieve an 
average steady-state concentration of 17.5 pg/ml was 
calculated. The actual dose given in each case was -80% 
of the calculated dose. This dose was given daily in two 
divided doses (every 12 h) for 7 days. During this inter- 
val, trough blood samples were taken every 48 h for 
measurement of whole blood and plasma levels. 
Withdrawal of one baseline drug 
On the eighth treatment day, each patient was admit- 
ted to the University of Michigan Clinical Research Cen- 
ter for -10 days. One baseline antiepileptic drug was 
withdrawn, and trough (8 a.m.) plasma levels of all 
antiepileptic drugs were sampled each day. Approxi- 
mated peak levels (11 a.m.) were sampled every other 
day. Doses of zonisamide were adjusted to achieve a 
plasma level of 15-40 &ml or reduced to eliminate side 
effects. 
Outpatient treatment period 
Once the plasma level of the drug withdrawn fell below 
15% of the initial level, the patient was discharged from 
the hospital and evaluated weekly for 4 weeks, and then 
every 2 weeks for the remainder of the 12-week treat- 
ment period. Evaluation procedures were identical to 
those done during the baseline period. Neuropsycholog- 
ical tests were administered on week 12 of treatment. 
RESULTS 
Pharmacokinetics of zonisamide 
The mean concentrations of zonisamide in plasma, 
whole blood, and red blood cells, following a single oral 
dose of 400 mg, are shown in Figure 1. The mean time 
to reach peak concentration (t,,,) following a single oral 
dose of 400 mg was 2.8 h [coefficient of variation (CV) 
37%] for plasma and 5.8 (CV 46%) for whole blood. 
The mean maximum concentration was 5.48 pg/ml (CV 
Epilepsia, Vol. 26. No. 3 ,  1985 
208 J .  C .  SACKELLARES ET AL.. 
TABLE 2. Concomitantly administered antiepileptic drugs 
~~ 
Plasma level (Fgiml) Weight Initial dose 
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FIG. 1. Mean concentrations of zonisamide in plasma (squares), 
whole blood (triangles), and red blood cells (RBC; circles) follow- 
ing a single oral dose of 400 mg. 
35.6%) for plasma and 13.4 pg/ml (CV 27.3%) for 
whole blood. The mean plasma clearance was 2.34 L/h 
(CV 36.6%). The mean plasma elimination rate constant 
was 0.0264 h-' (CV 26.9%). The calculated half-life 
was 28.4 h (CV 33.9%). Although maintenance doses 
were chosen to reach a mean steady-state plasma con- 
centration of 17.5 pg/ml, the actual steady-state levels 
tended to exceed the predicted value. The actual doses 
given every 12 h and the resultant average minimum 
steady-state concentrations in plasma are given in Table 
3. In most cases, the minimum steady-state plasma con- 
centration (Css, -) could be roughly estimated ( & 28%) 
from the single-dose data using a simple formula: 
Css,min = 1.81 R/CL, where CL is the plasma clearance 
and R is the daily dose. However, detailed analysis in- 
dicates that zonisamide follows Michaelis-Menten kinet- 
ics (Wagner et al., 1984). 
Drug-drug interactions 
The doses and plasma concentrations of concomitantly 
administered antiepileptic drugs are summarized in Ta- 
ble 2. For most drugs, the average plasma concentration 
during the baseline period was somewhat lower than the 
average concentration during treatment with zonisamide. 
There was a consistent rise in average carbamazepine 
concentrations following initiation of zonisamide therapy. 
Seizure control 
The effects on seizure control were measured in most 
cases by comparing the number of seizures during the 
8-week baseline period to the number of seizures during 
Epilepsia, Vol. 26, No. 3 ,  1985 
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TABLE 3. Average minimum steady-state concentrations of zonisamide as a 
function of dose 
Dose Plasma minimum steady-state 







































































the last 8 weeks of treatment (following substitution of 
zonisamide for one standard antiepileptic drug). These 
data are summarized in Table 4. Patient 5 was withdrawn 
from the study after 3 weeks because of a flurry of 
seizures. In retrospect, this flurry did not result from 
treatment with zonisamide, because similar flurries had 
occurred before the study and continued to occur fol- 
lowing discontinuation of administration of the drug. In 
this case, seizure frequency (number of seizures per 
week) was used to calculate the percentage change in 
seizures. Patient 10 did not provide an accurate report 
of seizures during the first 4 weeks of baseline; in this 
case, the last 4 weeks of baseline were compared with 
the last 4 weeks of the treatment period. One patient 
experienced complete seizure control following treat- 
ment with zonisamide. Four others had >75% improve- 
ment. All but one of the remaining five patients had at 
least 50% reduction in seizure frequency. Patient 6 had 
no change in seizure frequency but reported a reduction 
in seizure severity. Frequencies of simple partial and 
complex partial seizures were reduced in most patients. 
However, generalized seizures occurred slightly more 
often during the treatment period in two patients. 
Side effects and toxicity 
All observed or reported side effects are listed in Table 
5. No hematologic, hepatic, renal, cardiac, or other sys- 
temic toxic effects were observed. Side effects were 
observed or reported by all patients, but these were 
reversible or reduced to a tolerable level in each case. In 
TABLE 4. Comparison of seizure frequency during an 8-wk baseline period to 
seizure frequency in the last 8 wk of the treatment period 
No. of seizures 
Percentage Baseline Treatment 
Patient SP CP PG U Total SP CP PG U Total change 
1 30 1 31 3 5 5 2 1 5  - 52 
2 23 23 1 1 - 96 
3 196 9 205 24 2 26 - 87 
4 38 38 14 4 18 - 53 
5 224 224 (28/wk) 38 38 (12.7/wk)' -55 
6 1 7  8 2 1 2 3  8 0 
I 173 26 199 0 -100 
8 30b 30 1 1 - 97 
9 252c 252 17 20 37 - 85 
10 6 6 (1.5/wk) 3 3 (0.75/wk) -50d 
SP, simple partial seizures; CP, complex partial seizures; PG, partial evolving to generalized seizures; 
aThis patient was withdrawn from study after 3 weeks of zonisamide treatment. 
&Estimated minimum. Simple partial seizures were too numerous to count accurately. 
T h e  patient was not able to differentiate between simple and complex partial seizures because of the 
dNumber based on last 4 weeks of baseline and last 4 weeks of zonisamide treatment. 
U,  unclassified because of incomplete description. 
high seizure frequency. 
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TABLE 5. Observed or reported 
side effects 












Loss of appetite 5 
Weight loss 8 
Gustatory symptoms' 2 
Cold chillsn 2 
Numbness' 1 
"Reported by patients, but probably not drug 
related. 
no case did side effects necessitate withdrawal from the 
study. The most common side effects were weight loss, 
nystagmus, mild ataxia, drowsiness, and mild mental 
confusion. In one patient who exhibited paranoid idea- 
tion and withdrawn behavior, zonisamide was withdrawn 
briefly, and these problems resolved. However, the be- 
havior did not occur following reinstitution of the drug, 
and she continued taking the drug without side effects. 
Although symptoms and signs of toxicity appeared to 
occur primarily when plasma concentrations exceeded 
40 pg/ml, a clearly definable toxic plasma level could 
not be determined in this small number of patients. 
However, impaired performance on some of the formal 
measures of cognitive and psychomotor tasks appeared 
to be related to the plasma levels of zonisamide. The 
relationship between plasma levels and neuropsycholog- 
ical performance will be discussed in a subsequent pub- 
lication. 
Side effects were most frequent during the initial 2 
weeks of treatment with zonisamide. In some cases, side 
effects were associated with a rise in the plasma level of 
carbamazepine (three cases) or phenytoin (one case) and 
were resolved or markedly reduced after the dose of that 
drug was lowered. In seven patients, side effects were 
resolved or markedly improved after the dose of zoni- 
samide was reduced. The final maintenance dose, re- 
sulting in minimal or no side effects, ranged between 
5.2 and 12.5 mg/kg/day (mean * SD 8.5 -1- 2.5). The 
resultant plasma level ranged from 16.5 to 49.6 pg/ml 
(mean _+ SD 30.7 f 10.2). 
DISCUSSION 
The results of this study suggest that zonisamide may 
seizures was reduced after substitution of zonisamide for 
one of the baseline antiepileptic drugs. This observation 
must be interpreted cautiously. In an unblinded study 
with no control group, the possibilities of observer bias 
or placebo effects must be considered. It is conceivable 
that elimination of one of the baseline antiepileptic drugs 
could have improved seizure control. However, these 
preliminary observations indicate that a more definitive 
efficacy study, using a double-blind controlled protocol, 
is warranted. Clinically significant antiepileptic effects 
were observed with plasma levels between 16.5 and 49.6 
pg/ml. Dose-related side effects in the central nervous 
and gastrointestinal systems were observed. These ob- 
servations suggest that the therapeutic range predicted 
from animal studies, 10-70 pg/ml (Masuda et al., 1979), 
may represent a reasonable estimate, although toxicity 
may occur at levels well below 70 pg/ml. Further study 
will be required to achieve a more accurate estimation 
of the therapeutic range. Zonisamide is quickly absorbed 
from the gastrointestinal tract, having an average t,,, of 
2.8 h. The calculated average half-life in plasma is - 28 
h. However, this value may not be meaningful if, as we 
suspect, the drug follows concentration-dependent ki- 
netics (Wagner et al., 1984). 
The single-dose pharmacokinetic parameters observed 
in these patients were different from those reported in 
normal human volunteers by Ito et al. (1982). In that 
study, a single oral dose of 400 mg resulted in a mean 
peak plasma concentration of 13.4 p.g/ml, a mean t,,, 
of 5.3 h, and a mean elimination half-life of 56.7 h. 
These differences suggest the possibility of drug-drug 
interactions affecting the pharmacokinetics of zonisam- 
ide in patients receiving other antiepileptic drugs. The 
observed rise in level of concomitantly administered an- 
tiepileptic drugs, particularly carbamazepine, suggests 
the possibility that zonisamide may alter the pharmaco- 
kinetics of other drugs. 
The clearance from the plasma following a single oral 
dose provides a rough prediction of the doses required 
to achieve a given steady-state concentration. Doses be- 
tween 4 and 10 mg/kg/day should result in plasma levels 
in the expected therapeutic range. Zonisamide is highly 
bound to the red blood cell, resulting in high whole 
blood concentrations relative to plasma concentrations. 
The pharmacological and clinical implications of this red 
blood cell binding require further study. Zonisamide 
holds promise as a clinically useful antiepileptic drug. 
Further, more definitive efficacy studies and long-term 
safety and efficacy studies are in progress. 
APPENDIX 
be effective in controlling simple partial and complex 
partial seizures. In all but one case, the number of partial 
The following equations were used to calculate phar- 
macokinetic parameters: 
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In Cp = 1nC; - pt (applied to log-linear postpeak 
C, and t data) 
- CL, = dose/(AUC 0-m) 
C,, = dose/(CL,)T 
v, = CLJp  
tics on the kindled seizures in the neocortex, hippocampus and 
amygdala in rats. Arch Int Pharmacodyn Ther 1981;249: 16476.  
Masuda Y, Karasawa T, Shiraishi Y, Hori M, Yoshida K, Shimizu M. 
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drug. Arzneimittelforsch 1980;30:477-83. 
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Relationships between plasma concentrations of diphenylhydan- 
toin, phenobarbital, carbamazepine, and 3-sulfamoylmethyl-l,2- 
benzisoxazole (AD-810), a new anticonvulsant agent, and their 
anticonvulsant or neurotoxic effects in experimental animals. Epi- 
leosia 1979:20:623-33. 
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where 
CL, = 
P =  
cs, = 




H =  
CB = 
c, = 
-  7 
plasma clearance after the single dose of 
400 mg 
elimination rate constant 
area under the curve 
predicted average steady-state plasma con- 
centration assuming linear kinetics 
predicted minimum steady-state concentra- 
tion assuming linear kinetics 
volume of distribution in the p phase 
red blood cell 
fractional hematocrit 
whole blood concentration of zonisamide 
plasma concentration of zonisamide 
dosage interval (12 h) 
Note that after a 400-mg single dose, kinetics were 
essentially linear, and linearity was observed when post- 
peak C, was plotted on semilogarithmic graph paper 
versus time. Hence, estimation of CL,, V,, and p were 
perfectly valid. 
When the patients were dosed to steady state, the 
plasma levels increased to a sufficient magnitude that 
kinetics became nonlinear, and steady-state clearance 
averaged only -40% of single-dose CL,. 
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RESUME 
Un nouveau produit anticonvulsivant, le zonisamide (1,2 benzisox- 
azole-methylsulfonamide) a ett administri a 10 adultes atteints de 
crises partielles non contr6lCes par le traitement mCdical. Apr6s une 
dose unique orale de 400 mg, le pic du taux plasmatique survient en 
moyenne 2 h 1/2 aprks l’ingestion, et la clairance plasmatique moyenne 
est de 2,34 litres par heure. Les concentrations sanguines totales sont 
plus Clevtes que les concentrations plasmatiques, en raison de la liaison 
aux globules rouges. Les concentrations plasmatiques B 1’Ctat d’equi- 
libre sont plus ClevCes que celles que I’on peut ddduire d’un mod6le 
de cinttique lintaire. Chez la plupart des patients, la frtquence des 
crises a CtC rtduite par la substitution du zonisamide au traitement 
antikpileptique standard. Des effets secondaires doses-dependants et 
rkversibles ont CtC observts au niveau du syst6me nerveux central et 
du tube digestif. La plupart des patients ont tolCrk des doses entre 5.2 
et 12,5 mg/kg de poids par jour. 
(J. Roger, Marseille) 
RESUMEN 
En 10 adultos con ataques parciales refractarios a1 tratamiento m6d- 
ico, se ha estudiado la accidn de un nuevo compuesto anticonvulsivo, 
la zonisamida (1,2 benzisoxazol-metanosulfonamida). Tras la ingestidn 
de una sola dosis oral de 400 mg., se alcanzaron 10s niveles pic0 en 
plasma en un promedio de 2.8 horas desputs de la dosis y el aclara- 
miento medio del plasma fu6 de 2,34 litros/hora. Las concentraciones 
en sangre fueron mas altas que las plasmaticas debido a que la medi- 
cacidn se ligaba a 10s hematies. Las concentraciones plasmaticas est- 
ables fueron mis  altas que las previsibles de un modelo cinttico lineal. 
En la mayorfa de 10s pacientes la frecuencia de 10s ataques se redujo 
despuks de cambiar la medicacidn antiepilbptica standard por la zon- 
isamida. Tambitn se observaron 10s efectos colaterales sobre el tracto 
gastrointestinal y el sistema nervioso central que estaban relacionadas 
con la dosis y eran reversibles. La mayor parte de 10s pacientes tolero 
dosis que oscilaban entre 5.2 y 12.5 mglkgldia. 
(A. Portera Sanchez. Madrid) 
ZUS AMMENF ASSUNG 
Ein neues Antikonvulsivum, Zonisamid (1,2 Benzisoxazol-Methan- 
sulfonamid) wurde bei 10 Envachsenen mit therapieresistenten Parti- 
alanfallen gesucht. Nach einer oralen Einzeldosis von 400 mg wurden 
Plasmaspitzenwerte im Durchschnitt nach 2,8 Stunden erreicht. Die 
mittlere Clearance aus dem Plasma betrug 2,34 UStunde. Ganzblut- 
konzentrationen waren hoher als Plasmakonzentrationen aufgrund der 
Bindung an die roten Blutkorperchen. Die steady-state Plasmakonzen- 
trationen waren hoher als bei einem linearen kinetischen Model1 zu 
envarten. Bei den meisten Patienten konnte die Anfallsfrequenz nach 
Substitution eines Standardantiepileptikums durch Zonisamid reduziert 
werden. Es bestanden dosisabhangige, reversible, zentral-nervose und 
gastrointestinale Nebenwirkungen. Die meisten Patienten tolerierten 
Dosen zwischen 5,2 und 12,5 mg/kg/Tag. 
(D. Scheffner, Heidelberg) 
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